Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study

Erden et al., Bratislava Medical Journal, doi:10.4149/BLL_2022_018
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -150% Improvement Relative Risk Hospitalization 75% HCQ for COVID-19  Erden et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 9 patients in Turkey No significant difference in outcomes seen c19hcq.org Erden et al., Bratislava Medical J., Jan 2022 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 9 COVID-19 patients with antiphospholipid syndrome in Turkey, showing no significant differences based on existing HCQ treatment.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 150.0% higher, RR 2.50, p = 1.00, treatment 1 of 6 (16.7%), control 0 of 3 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 75.0% lower, RR 0.25, p = 0.23, treatment 1 of 6 (16.7%), control 2 of 3 (66.7%), NNT 2.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Erden et al., 23 Jan 2022, retrospective, Turkey, peer-reviewed, 11 authors.
This PaperHCQAll
COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
A Erden, O Karakas, B Armagan, S C Guven, B Ozdemir, E Atalar, H Apaydin, E Usul, I Ates, A Omma, O Kucuksahin
Bratislava Medical Journal, doi:10.4149/bll_2022_018
BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR-positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).
References
Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis, Ann Rheum Dis
Andreoli, Fredi, Nalli, Clinical signifi cance of IgA anticardiolipin and IgA anti-β2glycoprotein I antibodies, Curr Rheumatol Rep
Cavalli, Bramanti, Ciurleo, Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review), Int J Mol Med
Dosquet, Weill, Wautier, Cytokines and thrombosis, J Cardiovasc Pharmacol
Engelmann, Massberg, Thrombosis as an intravascular effector of innate immunity, Nature Rev Immunol
Glass, Subbarao, Murphy, Murphy, Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice, J Immunol
Gralinski, Sheahan, Morrison, Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis, mBio
Han, Yang, Liu, Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clin Chem Lab Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Hunt, A novel antiphospholipid antibody agent?, Blood
Klok, Kruip, Van Der Meer, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res
Li, Lu, Zhang, Clinical observation and management of CO-VID-19 patients, Emerg Microbes Infect
Mckee, Sternberg, Stange, Laufer, Naujokat, Candidate drugs against SARS-CoV-2 and COVID-19, Pharmacol Res
Mekinian, Lazzaroni, Kuzenko, SNFMI and the European Forum on Antiphospholipid Antibodies. The effi cacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study, Autoimmun Rev
Miesbach, Makris, COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation, Clin Appl Thromb Hemost
Miyakis, Lockshi N Md, Atsumi, International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS), J Thromb Haemost
Nalli, Andreoli, Casu, Tincani, Management of recurrent thrombosis in antiphospholipid syndrome, Curr Rheumatol Rep
Pablos, Abasolo, investigators group. Prevalence of hospital PCR-confi rmed COVID-19 cases in patients with chronic infl ammatory and autoimmune rheumatic diseases, Ann Rheum Dis2020
Rheumatism, Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Rodziewicz, Cruz, An update on the management of antiphospholipid syndrome, Ther Adv Musculoskelet Dis
Schmidt-Tanguy, Voswinkel, Henrion, Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients, J Thromb Haemost
Sciascia, Hunt, Talavera-Garcia, Lliso, Khamashta et al., The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies, Am J Obstet Gynecol
So, Mak, So, Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study, Semin Arthritis Rheum
Strangfeld, Schäfer, Gianfrancesco, 19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Taraborelli, Reggia, Dall'ara, Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study, J Rheumatol
Uthman, Gharavi, Viral infections and antiphospholipid antibodies, Semin Arthritis Rheum
Wallace, Gudsoorkar, Weisman, Venuturupalli, New insights into mechanisms of therapeutic effects of antimalarial agents in SLE, Nat Rev Rheumatol
Wilson, Gharavi, Koike, International consensus statement on preliminary classifi cation criteria for defi nite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum
Xiao, Zhang, Zhang, Antiphospholipid Antibodies in Critically Ill Patients With COVID-19, Arthritis Rheumatol
Zhang, Xiao, Zhang, Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19, N Engl J Med
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2022, 1, 23]], 'date-time': '2022-01-23T16:41:00Z', 'timestamp': 1642956060257}, 'reference-count': 0, 'publisher': 'AEPress, s.r.o.', 'issue': '02', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['BLL'], 'published-print': {'date-parts': [[2022]]}, 'DOI': '10.4149/bll_2022_018', 'type': 'journal-article', 'created': {'date-parts': [[2022, 1, 23]], 'date-time': '2022-01-23T16:11:50Z', 'timestamp': 1642954310000}, 'page': '120-124', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study'], 'prefix': '10.4149', 'volume': '123', 'author': [ {'given': 'A.', 'family': 'Erden', 'sequence': 'first', 'affiliation': []}, {'given': 'O.', 'family': 'Karakas', 'sequence': 'additional', 'affiliation': []}, {'given': 'B.', 'family': 'Armagan', 'sequence': 'additional', 'affiliation': []}, {'given': 'S. C.', 'family': 'Guven', 'sequence': 'additional', 'affiliation': []}, {'given': 'B.', 'family': 'Ozdemir', 'sequence': 'additional', 'affiliation': []}, {'given': 'E.', 'family': 'Atalar', 'sequence': 'additional', 'affiliation': []}, {'given': 'H.', 'family': 'Apaydin', 'sequence': 'additional', 'affiliation': []}, {'given': 'E.', 'family': 'Usul', 'sequence': 'additional', 'affiliation': []}, {'given': 'I.', 'family': 'Ates', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Omma', 'sequence': 'additional', 'affiliation': []}, {'given': 'O.', 'family': 'Kucuksahin', 'sequence': 'additional', 'affiliation': []}], 'member': '2638', 'container-title': ['Bratislava Medical Journal'], 'original-title': [], 'deposited': { 'date-parts': [[2022, 1, 23]], 'date-time': '2022-01-23T16:12:02Z', 'timestamp': 1642954322000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 0, 'journal-issue': {'issue': '02', 'published-online': {'date-parts': [[2022]]}}, 'URL': 'http://dx.doi.org/10.4149/bll_2022_018', 'relation': {}, 'ISSN': ['1336-0345'], 'issn-type': [{'value': '1336-0345', 'type': 'electronic'}], 'subject': ['General Earth and Planetary Sciences', 'General Environmental Science'], 'published': {'date-parts': [[2022]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit